ANDREW HAR LIMPER

This study shows that Pgm2 in Pneumocystis links glucose-phosphate metabolism to β-1,3-glucan synthesis and cell-wall integrity, making it a potential antifungal target.

This study shows that inhibiting RAD51 in fibroblasts reduces fibrosis by promoting apoptosis and metabolic changes.

This paper determines the maximum-tolerated dose and pharmacokinetics of ISFP10, a fungal PGM inhibitor, in mice, showing no safety concerns up to 100 mg/kg.

This study evaluates the safety and antifungal activity of ISFP10, a fungal PGM inhibitor, in mice, finding no toxicity and concentration-dependent growth inhibition of Candida species.

This study shows that inhibiting SLC1A5, a glutamine transporter, reduces fibrosis by altering fibroblast metabolism and function in a mouse model of lung fibrosis.

The paper finds that somatic mutations in diseased lung tissue correlate with reduced lung function and cell type proportions in COPD and IPF.